Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma

Article indépendant

MCINTURF, Geoffrey | YOUNGER, Kimberly | SANCHEZ, Courtney | WALDE, Charles | ABDALLAH, Al-Ola | AHMED, Nausheen | SHUNE, Leyla | SBOROV, Douglas W. | GODARA, Amandeep | MCCLUNE, Brian | SINCLAIR, Christian T. | MOHYUDDIN, Ghulam Rehman

Introduction:Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist palliative care (SPC) involvement and end-of-life care for patients with MM. Methods: We assessed all deceased patients with a diagnosis of MM who received care at a single institution from January 2010 to December 2019 and assessed SPC involvement. Results: We reviewed 456 deceased patients. Overall, 207 patients (45.4%) received SPC visits by clinicians during their disease, and 153 (33.5%) were on MM treatment in the month before death. Median time from SPC consultation to death was 1 month, with 42 (9.2%) of patients receiving SPC visits 6 or more months before death. Amongst the patients for which a place of death was reported (351), 117 (33.3%) died in the acute care setting. Outpatient SPC did not correlate with a reduction of death in the acute care setting. In the group of patients who received outpatient SPC, 22/84 (26.2%) died in an acute care setting, whereas 95/267 (35.5%) patients who did not receive outpatient SPC also died in an acute care setting, (p = .11). Conclusion: In our analysis of the entire trajectory of the MM patient experience from diagnosis to death, we found low rates of SPC involvement and a significant proportion of patients receiving aggressive care at end-of-life. While there is no clear correlation that SPC involvement impacted the rate of acute care deaths or decreased utilization of MM treatment in the last month of life, further prospective research on optimal utilization of SPC is required.

http://dx.doi.org/10.1111/ejh.13843

Voir la revue «European journal of haematology»

Autres numéros de la revue «European journal of haematology»

Consulter en ligne

Suggestions

Du même auteur

Palliative care utilization, transfusion burd...

Article indépendant | MCINTURF, Geoffrey | European journal of haematology

Introduction:Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist palliative care (SPC) involvement and end-of-life care for patients with MM. Me...

Quality of end-of-life care in multiple myelo...

Article | MOHYUDDIN, Ghulam Rehman | British journal of haematology

Optimizing end-of-life (EOL) care for multiple myeloma (MM) represents an unmet need. An administrative cohort in Ontario, Canada was analysed between 2006 and 2018. Aggressive care was defined as two or more emergency-department ...

Quality of end-of-life care in multiple myelo...

Article indépendant | MOHYUDDIN, Ghulam Rehman | British journal of haematology

Optimizing end-of-life (EOL) care for multiple myeloma (MM) represents an unmet need. An administrative cohort in Ontario, Canada was analysed between 2006 and 2018. Aggressive care was defined as two or more emergency-department ...

De la même série

Palliative care utilization, transfusion burd...

Article indépendant | MCINTURF, Geoffrey | European journal of haematology

Introduction:Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist palliative care (SPC) involvement and end-of-life care for patients with MM. Me...

Comparing end-of-life care of hematologic mal...

Article indépendant | BURSTEIN, Rachel | European journal of haematology

Objectives: To compare end-of-life (EOL) care for solid tumor and hematologic malignancy (HM) patients. Methods: We collected data on the last 100 consecutive deceased HM and 100 consecutive deceased solid tumor patients who died ...

Treatment sequences and drug costs from diagn...

Article indépendant | SEEFAT, M. R. | European journal of haematology

Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End-of-life phases of treatment are generally the most expensive, however, these high costs may be less just...

Chargement des enrichissements...